On November 23, 2020 Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, reported they will participate in a fireside chat at the 2020 Evercore ISI HealthCONx Conference on Tuesday, December 1st at 8:20 a.m. PT/11:20 a.m. ET. Dan Faga, Executive Vice President and Chief Operating Officer, will represent Mirati at the event (Press release, Mirati, NOV 23, 2020, https://www.prnewswire.com/news-releases/mirati-therapeutics-to-participate-in-the-2020-evercore-isi-healthconx-conference-301179205.html [SID1234571607]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The webcast will be available through the "Investors" section of the Mirati website at View Source, and a replay of the webcast will be made available for 90 days following the event.

On November 23, 2020 Exelixis, Inc. (Nasdaq: EXEL) reported that members of the company’s management team will participate in fireside chats at the following virtual investor conferences in December (Press release, Exelixis, NOV 23, 2020, View Source [SID1234571606]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Piper Sandler 32nd Annual Virtual Healthcare Conference: Due to the virtual nature of this year’s conference, presentation sessions were pre-recorded and available on-demand. Exelixis’ fireside chat session is now available to stream on the company’s website.
Evercore ISI 3rd Annual HealthCONx: Exelixis is scheduled to present at 3:05pm EST / 12:05pm PST on Tuesday, December 1, 2020.
To access the webcast links, log onto www.exelixis.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading. Please connect to the company’s website at least 15 minutes prior to the presentations to ensure adequate time for any software download that may be required to listen to the webcasts. Replays will also be available at the same location for 14 days.

On November 23, 2020 Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, reported that management will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference, December 1-3, 2020 (Press release, Castle Biosciences, NOV 23, 2020, View Source [SID1234571605]). Derek Maetzold, president and chief executive officer, and Frank Stokes, chief financial officer, will provide a pre-recorded investor presentation and will be available for virtual one-on-one investor meetings during the conference.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Meetings may be requested exclusively through Piper Sandler. The pre-recorded company presentation will be available via the Piper Sandler conference site from November 23 to December 3 and on the Castle Biosciences website at View Source

On November 23, 2020 Novellus, Ltd., a clinical-stage biotechnology company focused on precision oncology, and Tempus, a leader in artificial intelligence and precision medicine, reported their collaboration to accelerate patient enrollment for Novellus’ next generation BRAF inhibitor program (Press release, Novellus, NOV 23, 2020, View Source [SID1234571604]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Novellus’ BRAF program focuses on patient populations for which there are currently no FDA-approved BRAF inhibitors, including BRAF fusions and BRAF-mutated gliomas. Novellus will participate in Tempus’s TIME Trial Network, and the companies will work together to identify relevant patients to accelerate patient enrollment.

"The collaboration with Tempus will enable us to accelerate the enrollment of patients in our BRAF trial, by precisely identifying potential candidates and opening sites wherever the patients are found" said Michael Vidne, Chief Executive Officer of Novellus.

"The TIME Trial Program has achieved an unparalleled scale thus far, with over 50 provider networks and 2,500 oncologists included in its network," said Kim Blackwell, Chief Medical Officer of Tempus. "We’re excited to collaborate with Novellus, to further our mission to increase trial participation, and to ultimately bring the right treatment to the right patients at the right time."

On November 23, 2020 Imago BioSciences, Inc. ("Imago") a clinical-stage biopharmaceutical company developing innovative treatments for myeloproliferative neoplasms, reported its participation in the Piper Sandler 32nd Annual Healthcare Conference to be held virtually December 1 – 3, 2020 (Press release, Imago BioSciences, NOV 23, 2020, View Source [SID1234571601]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Hugh Young Rienhoff, Jr. M.D., chief executive officer of Imago BioSciences, will participate in a fireside chat with Christopher Andrews. The fireside chat will be pre-recorded and available on the Piper Sandler website to registered attendees beginning on Monday, November 23, 2020 at 10:00 am ET. The Company will host the one-on-one meetings with investors on Monday, November 30, 2020, meetings can be requested exclusively via Piper Sandler.